Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

October 24, 2024 08:01 ET | Source: Intellia Therapeutics, Inc.

Intellia Presents Positive Results from the Phase 2 Study of NTLA-2002, an Investigational In Vivo CRISPR Gene Editing Treatment for Hereditary Angioedema (HAE)

Deep attack rate reductions achieved in both dose levels tested; a single 50 mg dose resulted in a mean monthly attack rate reduction of 77% and 81% compared to placebo during weeks 1-16 and 5-16,...
October 07, 2024 07:30 ET | Source: Intellia Therapeutics, Inc.

Intellia Therapeutics Announces Initiation of HAELO Phase 3 Study of NTLA-2002, an Investigational In Vivo CRISPR Gene Editing Treatment for Hereditary Angioedema (HAE)

NTLA-2002 is a single-dose treatment designed to prevent potentially life-threatening swelling attacks in people with hereditary angioedema (HAE)NTLA-2002 is Intellia’s second in vivo candidate to...
September 12, 2024 07:30 ET | Source: Intellia Therapeutics, Inc.

Intellia Therapeutics to Present Data from the Phase 2 Study of NTLA-2002 for the Treatment of Hereditary Angioedema (HAE) at the 2024 ACAAI Annual Scientific Meeting

First presentation of detailed Phase 2 results following previous positive topline announcement that study of NTLA-2002 met primary and all secondary endpoints Intellia to host investor webcast on...
March 02, 2023 07:00 ET | Source: Intellia Therapeutics, Inc.

Intellia Therapeutics Announces FDA Clearance of Investigational New Drug (IND) Application for NTLA-2002, an In Vivo CRISPR-Based Investigational Therapy for the Treatment of Hereditary Angioedema (HAE)

CAMBRIDGE, Mass., March 02, 2023 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focused on developing potentially curative therapies...
September 16, 2022 07:00 ET | Source: Intellia Therapeutics, Inc.

Intellia Therapeutics Announces Positive Interim Clinical Data for its Second Systemically Delivered Investigational CRISPR Candidate, NTLA-2002 for the Treatment of Hereditary Angioedema (HAE)

Positive interim clinical data further validate the modularity of Intellia’s industry-leading genome editing platform and its potential to target a multitude of genetic diseases A single dose of...
December 20, 2021 10:16 ET | Source: Visiongain Ltd

Hereditary Angioedema Treatment Market Report Up to 2031: Visiongain Research Inc

Visiongain has published a new report on Hereditary Angioedema Treatment Market Report 2021-2031: Forecasts By Drug Class (C1-esterase Inhibitor, Bradykinin B2 Receptor Antagonist, Kallikrein...
December 20, 2021 10:14 ET | Source: Visiongain Ltd

Geriatric Medicines Market Report Up to 2031: Visiongain Research Inc

Visiongain has published a new report on Geriatric Medicines Market Report 2021-2031: Forecasts By Therapeutic Category (Analgesic, Antihypertensive, Statins, Antidiabetic, Proton Pump Inhibitor,...
December 13, 2021 07:30 ET | Source: Intellia Therapeutics, Inc.

Intellia Therapeutics Announces First Patient Dosed in Phase 1/2 Clinical Trial of NTLA-2002 for the Treatment of Hereditary Angioedema

CAMBRIDGE, Mass., Dec. 13, 2021 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focused on developing curative therapeutics using...
October 19, 2018 08:00 ET | Source: Shire plc

Shire plc: CHMP Recommends EU Marketing Authorisation of lanadelumab for the Prevention of HAE Attacks

CHMP Recommends EU Marketing Authorisation of lanadelumab for the Prevention of HAE Attacks - If approved, lanadelumab would be the first monoclonal antibody for the preventive treatment of...